Chester Porphyria Treatment & Management
- Author: Koyamangalath Krishnan, MD, FRCP, FACP; Chief Editor: Emmanuel C Besa, MD more...
See the list below:
- Currently, no cure exists for Chester porphyria. The goal of management is to avoid precipitating factors in cases of suspected porphyrias.
- Treatment is symptomatic.
- Genetic counseling and understanding the disease and its manifestations may be helpful for family members.
Patients with Chester porphyria are at risk of an acute attack of porphyria at the time of surgery. This is because of stress, metabolic abnormalities, and certain drugs used during surgery.
Poblete-Gutiérrez P, Wiederholt T, Martinez-Mir A, et al. Demystification of Chester porphyria: a nonsense mutation in the porphobilinogen deaminase gene. Physiol Res. 2006. 55 suppl 2:S137-44. [Medline]. [Full Text].
Youngs GR, ed. Dobson's Complaint: The Story of the Chester Porphyria. London, England: The Royal College of Physicians of London; 1998.
McColl KE, Thompson GG, Moore MR, et al. Chester porphyria: biochemical studies of a new form of acute porphyria. Lancet. 1985 Oct 12. 2(8459):796-9. [Medline].
Qadiri MR, Church SE, McColl KE, Moore MR, Youngs GR. Chester porphyria: a clinical study of a new form of acute porphyria. Br Med J (Clin Res Ed). 1986 Feb 15. 292(6518):455-9. [Medline]. [Full Text].
Bonkowsky HL, Schady W. Neurologic manifestations of acute porphyria. Semin Liver Dis. 1982 May. 2(2):108-24. [Medline].
Norton B, Lanyon WG, Moore MR, et al. Evidence for involvement of a second genetic locus on chromosome 11q in porphyrin metabolism. Hum Genet. 1993 Jul. 91(6):576-8. [Medline].
Pischik E, Kazakov V, Kauppinen R. Is screening for urinary porphobilinogen useful among patients with acute polyneuropathy or encephalopathy?. J Neurol. 2008 Jul. 255(7):974-9. [Medline].
Billoo AG, Lone SW. A family with acute intermittent porphyria. J Coll Physicians Surg Pak. 2008 May. 18(5):316-8. [Medline].
Church SE. The Chester porphyria. MD thesis, University of Liverpool, United Kingdom. 1986.
Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and pharmacodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007. 46(4):335-49. [Medline].